Appearance of anticoagulant factors and certain “Autoimmune” antibodies following antigenic stimulation with blood group substances in patients with systemic lupus erythematosus

Zingale, Salvador B.; Ávalos, Julio César Sánchez; Andrada, J A; Stringa, S. G.; Manni, Jorge A.

doi:10.1002/art.1780060503

Cited by 33 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some authors have reported enhanced antibody production (29,30), while others have found normal (20,21,24,26) or diminished (28,31) antibody production in patients with SLE (8,21). Our study results are comparable with previous reports of decreased antibody titers in SLE patients compared with controls (5,22,28,31).…”

Section: Discussionsupporting

confidence: 87%

Antigen-specific antibody responses in lupus patients following immunization

Larsen

et al. 1998

Arthritis & Rheumatism

131

View full text Add to dashboard Cite

Objective To determine the safety and efficacy of 3 clinically relevant vaccines in patients with systemic lupus erythematosus (SLE). Methods We studied 73 consecutive SLE patients immunized with pneumococcal, tetanus toxoid (TT), and Haemophilus influenzae type B (HIB) vaccines. Patients were evaluated preimmunization and 12 weeks postimmunization for disease activity and immunization side effects. Results Eighty‐four percent of the SLE patients developed a 4‐fold titer increase in response to at least 1 vaccine, with 51% developing a 2‐fold titer increase with all 3 vaccines. The majority of SLE patients developed protective levels of antibody to TT (90%) and HIB (88%). Although protective antibody levels could not be determined for pneumococcus, almost half of the patients (47%) developed a 4‐fold antibody response. There was a trend toward a lower antibody response in patients with active disease treated with immunosuppressive therapy. Overall lupus disease activity was unaffected by immunization. Conclusion Immunization is safe in SLE patients, with the overwhelming majority developing protective antibody levels. Therefore, SLE patients should receive immunizations according to the recommendations of the Centers for Disease Control and Prevention and the Immunization Practices Advisory Committee.

show abstract

Section: Discussionsupporting

confidence: 87%

Antigen-specific antibody responses in lupus patients following immunization

Larsen

et al. 1998

Arthritis & Rheumatism

131

View full text Add to dashboard Cite

show abstract

“…SLE patients showed decreased levels ofantibodies to streptolysin 0 (26) and of natural antibodies to Escherichia coli and Shigella antigens (28). On the other hand, elevated SLE antibody responses were found against penicillin (29), blood group antigens (30), and a variety of viral antigens (31)(32)(33)(34)(35) (37). However, other studies have indicated that the helper T cell and the antigen-reactive, proliferating T cell might not be the same cell (39)(40)(41).…”

Section: Methods Cell Isolations Peripheral Blood Mononuclear Cells mentioning

confidence: 99%

Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen.

Gottlieb¹,

Lahita²,

Chiorazzi³

et al. 1979

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T Peripheral blood mononuclear cells from 46 systemic lupus erythematosus (SLE) patients showed reduced ability to proliferate in vitro in response to the soluble antigen, tetanus toxoid, as compared with 96 normal controls. Special studies of27 untreated SLE patients also revealed significantly decreased blastogenic responses to tetanus toxoid. In both the total and untreated SLE populations, decreased mean tetanus antibody titers also were found as compared with the control population. However, the reduction in antibody titer and blastogenic response was not strictly parallel.

show abstract

“…Previous studies have reported an increased antibody response in patients with systemic lupus erythematosis (SLE) after immunization with Brucella (1) and incompatible erythrocytes (2), and a normal or decreased Dr. Baum is a Clinical Scholar of the Arthritis Foundation. His present address is Department of Medicine, University of Rochester School of Medicine, Rochester, N. Y.…”

Section: Introductionmentioning

confidence: 99%